Oklahoma Healthcare Wire
SEE OTHER BRANDS

Fresh health and wellness news from Oklahoma

Oklahoma Healthcare Wire: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oklahoma Healthcare Wire.

Press releases published on July 10, 2025

Privia Health to Report Second Quarter 2025 Results on Thursday, August 7

Privia Health to Report Second Quarter 2025 Results on Thursday, August 7

ARLINGTON, Va., July 10, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its second-quarter and six-month periods ended June 30, 2025 before market open on Thursday, August …

Radical Catheter Technologies’ 8F Neurovascular Guide Catheter Demonstrates Outstanding Clinical Performance in Initial Cases

Radical Catheter Technologies’ 8F Neurovascular Guide Catheter Demonstrates Outstanding Clinical Performance in Initial Cases

LOS GATOS, calif., July 10, 2025 (GLOBE NEWSWIRE) -- Radical Catheter Technologies™, a pioneering medical device company and a NeuroTechnology Investors (NTI) portfolio company focused on advancing the next generation of endovascular access and delivery, …

MMI’s Symani® System Redefines Robotic Microsurgery Again with First-Ever Dissection and Digital Surgery Capabilities

MMI’s Symani® System Redefines Robotic Microsurgery Again with First-Ever Dissection and Digital Surgery Capabilities

JACKSONVILLE, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Medical Microinstruments, Inc. (MMI), a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions, today announced the first …

Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership

Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership

SEATTLE, July 10, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, LLC, a wholly owned subsidiary of Fifty 1 Labs, Inc. (OTC: FITY), in collaboration with premier academic institutions including Stanford University, Duke University, McMaster University …

BioStem Technologies to Present at the Advanced Wound Care Summit in Boston on July 15, 2025, at 2:00 PM ET

BioStem Technologies to Present at the Advanced Wound Care Summit in Boston on July 15, 2025, at 2:00 PM ET

POMPANO BEACH, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that …

SS Innovations Announces Completion of World’s First Robotic Telesurgery for Weight Loss with the Company’s SSi Mantra 3 Surgical Robotic System

SS Innovations Announces Completion of World’s First Robotic Telesurgery for Weight Loss with the Company’s SSi Mantra 3 Surgical Robotic System

Led by Dr. Mohit Bhandari, a pioneer in bariatric surgery and President of the Institute of Research Against Digestive Cancer (IRCAD) India, the surgery was remotely performed at a distance of 560 miles and executed on-site at Mohak Bariatric …

The International Myeloma Foundation’s Brian D. Novis Research Grants: Celebrating 30 Years of Paving the Way for Transformative Breakthroughs in Myeloma Research

The International Myeloma Foundation’s Brian D. Novis Research Grants: Celebrating 30 Years of Paving the Way for Transformative Breakthroughs in Myeloma Research

STUDIO CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is proud to announce the 30th anniversary of the Brian D. Novis (BDN) Research Grant Program. To honor the memory of its co-founder, the Brian D. Novis …

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform  Landscape of Cancer Treatment

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN ( …

Dentsply Sirona to Host Second Quarter Conference Call on August 7th

Dentsply Sirona to Host Second Quarter Conference Call on August 7th

CHARLOTTE, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, August 7, 2025, at 8:30 am ET …

Intelligent Bio Solutions to Present PK Study Data at Association for Diagnostics and Laboratory Medicine 2025 Clinical Lab Expo

Intelligent Bio Solutions to Present PK Study Data at Association for Diagnostics and Laboratory Medicine 2025 Clinical Lab Expo

Data shows excretion of codeine in fingerprint sweat INBS’ System is viable option for non-invasive diagnostic testing NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology …

OSS Announces $2 Million Follow-On Production Order from Innovative Medical Imaging OEM

OSS Announces $2 Million Follow-On Production Order from Innovative Medical Imaging OEM

ESCONDIDO, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- One Stop Systems, Inc. (OSS or the Company) (Nasdaq: OSS), a leader in rugged Enterprise Class compute for artificial intelligence (AI), machine learning (ML) and sensor processing at the edge, today …

e-therapeutics De-risks Clinical Path for GalOmic Candidate ETX-312 with Positive Non-clinical Data

e-therapeutics De-risks Clinical Path for GalOmic Candidate ETX-312 with Positive Non-clinical Data

ETX-312 well tolerated at exaggerated dose levels in GLP-compliant toxicology studies GMP manufacturing of clinical trial batch successfully completed On track for CTA submission in Q4 2025 LONDON, July 10, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a …

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

PRINCETON, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced …

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference

BOTHELL, Wash., July 10, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its first-in-class pan-viral protease inhibitor CDI-988 has been selected for an oral presentation at the 9th International Calicivirus Conference being …

Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum

Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum

ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies Once-daily topical prescription medication can be applied by patients, parents and caregivers …

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025

NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s …

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially launched ZELSUVMI™ (berdazimer) topical gel 10.3%, the …

TerrAscend to Host Second Quarter 2025 Earnings Conference Call

TerrAscend to Host Second Quarter 2025 Earnings Conference Call

TORONTO, July 10, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today announced that it will host a scheduled conference call to discuss the results for its …

Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) NEW YORK and NORTH CHICAGO, Ill., July 10, 2025 (GLOBE NEWSWIRE) -- IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos …

Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease

Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease

PURCHASE, N.Y., July 10, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted an end-of-Phase 2 meeting with the U.S. …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service